StockNews.com upgraded shares of MiMedx Group (NASDAQ:MDXG – Free Report) from a buy rating to a strong-buy rating in a research report released on Thursday morning.
MDXG has been the topic of a number of other reports. Craig Hallum decreased their target price on MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Cantor Fitzgerald reissued an “overweight” rating and issued a $11.00 price target on shares of MiMedx Group in a research note on Thursday, August 1st. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, MiMedx Group currently has an average rating of “Buy” and a consensus price target of $12.00.
Read Our Latest Stock Analysis on MDXG
MiMedx Group Price Performance
MiMedx Group (NASDAQ:MDXG – Get Free Report) last issued its earnings results on Wednesday, July 31st. The company reported $0.08 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.08. The firm had revenue of $87.21 million during the quarter, compared to analysts’ expectations of $88.44 million. MiMedx Group had a net margin of 23.86% and a return on equity of 27.28%. Analysts anticipate that MiMedx Group will post 0.26 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of MDXG. Headlands Technologies LLC acquired a new stake in MiMedx Group during the 1st quarter worth about $27,000. Blue Trust Inc. purchased a new stake in shares of MiMedx Group in the third quarter worth approximately $30,000. Point72 Asset Management L.P. acquired a new stake in shares of MiMedx Group during the second quarter worth approximately $40,000. Quest Partners LLC purchased a new position in MiMedx Group during the second quarter valued at approximately $81,000. Finally, Entropy Technologies LP acquired a new position in MiMedx Group in the 1st quarter valued at approximately $99,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.
About MiMedx Group
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Recommended Stories
- Five stocks we like better than MiMedx Group
- Why Invest in High-Yield Dividend Stocks?
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- Election Stocks: How Elections Affect the Stock Market
- Top Nuclear Stocks Thriving on Soaring Energy Demand
- 10 Best Airline Stocks to Buy
- Apple Earnings – When Really Good Just Isn’t Good Enough
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.